United Therapeutics Corporation (UTHR)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 1,697,200 | 1,207,700 | 961,200 | 894,800 | 738,700 |
| Short-term investments | US$ in thousands | 1,569,800 | 1,786,400 | 1,877,500 | 1,035,900 | 1,096,300 |
| Receivables | US$ in thousands | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 738,100 | 804,400 | 343,200 | 305,400 | 323,300 |
| Quick ratio | 4.43 | 3.72 | 8.27 | 6.32 | 5.68 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($1,697,200K
+ $1,569,800K
+ $—K)
÷ $738,100K
= 4.43
The quick ratio of United Therapeutics Corporation has shown a generally positive trend over the past five years. Starting at 5.68 in December 2020, the ratio improved to 6.32 by December 2021 and further increased to 8.27 by December 2022, indicating a strong ability to cover its short-term obligations with its most liquid assets. However, there was a slight decline in the ratio to 3.72 by December 2023, which may suggest a lower level of liquidity or an increase in current liabilities relative to liquid assets. The ratio improved again to 4.43 by December 2024, although it remains below the peak reached in 2022. Overall, the company has maintained a healthy quick ratio above 1 throughout the period, indicating a strong ability to meet its short-term liabilities with its quick assets.
Peer comparison
Dec 31, 2024